文献速递慢阻肺

COPD急性加重识别工具(CERT)的验证与进一步分析

Validation and Further Analysis of the COPD Exacerbation Recognition Tool (CERT).
PubMed 文献 · Respirology · 2025-11-19

本研究在中国三家三级医院纳入稳定期和急性加重期COPD患者,以GOLD 2021标准下的医生诊断为参照,验证CERT的敏感度和特异度。原版CERT敏感度92.4%、特异度72.1%;评分版取切点6时敏感度94.3%、特异度86.9%,与医生诊断一致性更高(kappa 0.833 vs 0.666)。探索性因子分析提取两个成分,累积方差82.3%。

要点

  • 原版CERT敏感度92.4%、特异度72.1%,可用于识别COPD急性加重。
  • 评分版CERT切点6时敏感度94.3%、特异度86.9%,一致性优于原版。
  • 两成分结构(咳嗽咳痰、气促活动受限)累积方差82.3%,两条目评分版亦有效。

核心结论

  • 原版和评分版CERT均有良好敏感度和特异度,评分版与医生诊断一致性更好。
  • 采用两个代表性条目的两条目评分版也能有效识别急性加重。

研究设计与样本

  • 在中国三家三级医院纳入稳定期和急性加重期COPD患者。
  • 以GOLD 2021标准下医生诊断为参照,比较患者CERT回答。
  • CERT按推荐方式及总分方式(五个症状变化程度赋分,总分15)评估。
  • 采用探索性因子分析识别CERT关键成分并可能减少条目数。

主要发现

  • 原版CERT敏感度92.4%、特异度72.1%。
  • 评分版CERT切点6时敏感度94.3%、特异度86.9%。
  • 评分版与医生诊断一致性kappa 0.833,原版为0.666。
  • 探索性因子分析提取两个成分「咳嗽咳痰」和「气促活动受限」,累积方差82.3%。

关键数值与推荐

  • 评分版CERT切点值为6时敏感度94.3%、特异度86.9%。
  • 原版CERT敏感度92.4%、特异度72.1%。
  • 评分版kappa 0.833,原版kappa 0.666。
  • 两成分累积方差82.3%。

临床怎么用

  • 可用CERT帮助COPD患者识别急性加重 onset 并就医。
  • 评分版CERT切点6可作为识别急性加重的参考。
  • 两条目评分版也可用于识别急性加重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The COPD Exacerbation Recognition Tool (CERT) contains five symptoms that may change at the onset of an exacerbation. It was designed to help patients with COPD recognise the onset of an exacerbation and seek medical attention. This study tested its sensitivity and specificity and further examined its properties. METHODS: Stable and exacerbating patients presenting to three tertiary hospitals in China were enrolled. Patients' responses to the CERT were compared with physicians' diagnoses made using GOLD 2021 criteria. The CERT was assessed as recommended, and as a total score, using scores assigned to the degree of change for each of the five symptoms (total score 15). Exploratory factor analysis (EFA) was used to identify the key components of the CERT and potentially reduce the number of items. RESULTS: Sensitivity and specificity of the original CERT were 92.4% and 72.1%. Using a cut-off value of 6, the score-based CERT had the better sensitivity (94.3%) and specificity (86.9%). Concordance between CERT and physician diagnosis was higher with the scored version (kappa 0.833) versus the original version (kappa 0.666). Using EFA, two components were identified 'cough and sputum' and 'breathlessness and activity limitation' with a cumulative variance of 82.3%. CONCLUSION: The original and scored-based CERT both had good sensitivity and specificity, but the score-based version showed better concordance with physician diagnosis. The use of two representative items in a 2-item scored version was also effective in identifying acute exacerbations. TRIAL REGISTRATION: ChiCTR2400090589 registered with https://www.chictr.org.cn.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Xing, Liu, Jones, et al. Validation and Further Analysis of the COPD Exacerbation Recognition Tool (CERT). Respirology. 2025. PMID: 41261057. doi:10.1002/resp.70159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。